Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q4 2026), with sales up 5.5% year on year to $88.35 billion. Its non-GAAP profit of $4.66 per share was 1.9% above analysts’ consensus estimates.
Is now the time to buy COR? Find out in our full research report (it’s free for active Edge members).
Cencora (COR) Q3 CY2026 highlights:
- Revenue $88.35 billion vs S&P analysts’ estimates of $88.28 billion (5.5% year-on-year growth, in line)
- Adjusted EPS $4.66 vs S&P analysts’ estimates of $4.57 (1.9% beat)
- Adjusted EPS guidance $19.58 at the midpoint for fiscal 2027, missing analyst estimates by 1%
- Operating margin 1%, up from 0% in the same quarter last year
- Market capitalization $67.55 billion
StockStory’s take
Cencora delivered calendar Q3 2026 results that aligned with market expectations on revenue and topped analyst profit forecasts. Management credited the quarter’s performance to strong growth in specialty pharmaceuticals, driven by recent acquisitions such as OneOncology and the expansion of its management services organization (MSO) platform. CEO Bob Mauch highlighted these investments as central to Cencora’s ability to support pharmaceutical-centric care, noting increased activity in specialty biologics and community-based care partnerships. The company also pointed to operational improvements and focused execution across its core distribution businesses as key contributors.
Looking ahead, Cencora’s guidance is shaped by its evolving segment structure and continued investment in specialty pharmaceuticals and provider services. Management expects high-teens operating income growth in specialty, supported by the full-year impact of recent MSO acquisitions and the anticipated launch of new oncology products. CFO Eva Boratto reiterated that capital allocation remains balanced between reinvestment, strategic M&A, and shareholder returns. Management also acknowledged potential headwinds from customer volume shifts, foreign exchange, and divestitures, but emphasized confidence in sustaining long-term earnings growth through its specialty focus and operational scale.
Key insights from management’s remarks
Management attributed the quarter’s momentum to the expansion of its specialty platform, new reporting structure, and targeted divestitures that sharpened strategic focus.
- Specialty platform expansion: The acquisition of OneOncology and agreements to acquire EyeSouth’s retina business and American Oncology Network extended Cencora's reach in high-growth specialty markets, particularly oncology and retina, enhancing relationships with both manufacturers and community providers.
- MSO platform growth: Cencora’s management services organizations (MSOs) deepened engagement with independent specialty practices, supporting clinical trial participation and practice management while contributing approximately 10% of enterprise operating income for the year.
- Portfolio simplification: Divestitures of non-core businesses allowed Cencora to focus capital and management attention on segments where it can generate higher returns, though management acknowledged near-term financial headwinds from these actions.
- Segment reorganization: The newly established Specialty Pharmaceutical and Provider Services segment consolidates specialty assets under unified leadership, aiming to improve execution, customer alignment, and transparency for investors.
- Specialty product pipeline: Management cited a growing pipeline of complex therapies, with over 100 new oncology products expected through 2030, supporting long-term demand for Cencora’s specialty logistics and distribution capabilities.
Drivers of future performance
Cencora’s outlook centers on accelerating specialty growth, ongoing MSO integration, and navigating portfolio changes as it targets higher operating income and EPS.
- Specialty-driven growth: The company expects specialty pharmaceuticals to drive high-single to low-double digit revenue gains, with MSO acquisitions and a robust pipeline of new therapies fueling above-average operating income growth in the segment.
- Portfolio and customer shifts: Management highlighted divestitures, the anticipated MWI Animal Health and Covetrus merger, and customer volume transitions as meaningful headwinds, expected to dampen consolidated growth rates but clarify the company’s long-term focus.
- Capital allocation and investment: Cencora plans $1 billion in capital expenditures focused on supply chain, digital infrastructure, and MSO platforms, while maintaining balanced capital deployment between M&A, share repurchases, and dividends.
Catalysts in upcoming quarters
In the coming quarters, our analysts will monitor (1) the pace and impact of MSO and specialty asset integration, (2) execution on the new segment structure and its effect on operational efficiency, and (3) the progression of planned divestitures and the MWI Animal Health–Covetrus merger. We will also track the effect of new specialty product launches and related reimbursement changes.
Cencora currently trades at $354.01, up from $340.50 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.